Anti-oxidant therapy in Alzheimer's disease
阿尔茨海默病的抗氧化治疗
基本信息
- 批准号:7794971
- 负责人:
- 金额:$ 25.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-02-15 至 2011-12-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdvanced Glycosylation End ProductsAlzheimer&aposs DiseaseAmyloidAntioxidantsApoptosisApplications GrantsBiological AssayBrainChronicClinical TrialsDetectionDiseaseEffectivenessFluorescenceFluorescent ProbesFree RadicalsGenerationsGinkgo biloba extractGliosisImageImaging TechniquesIn VitroLifeLigandsMeasuresMediatingMicroscopyMonitorNeurologicNeuronal DysfunctionNeuronsOutcome MeasureOxidative StressPathogenesisPatientsPeptidesReactive Oxygen SpeciesReaderReporterResearch PersonnelSenile PlaquesSorting - Cell MovementSourceSpectrum AnalysisStressStructureSynapsesTechniquesTestingTissuesToxic effectTransgenic MiceVitamin Eantioxidant therapybasebrain tissueeffective therapyfunctional outcomesgrape seed extracthigh throughput screeningin vivomouse modeloxidationoxidative damageperoxidationpreventtherapeutic target
项目摘要
Alzheimer's disease (AD) is a devastating neurological illness with no known cure, yet a central hypothesis
implicating oxidative stress as a cause of the disease has been postulated for more than a decade. AD is
characterized in post-mortem tissue by the presence of senile plaques that result from the progressive brain
accumulation of amyloid-p (A(3)peptides; thus Ap is the principle therapeutic target for treating AD. There
are numerous studies with anti-oxidant therapy, however none examine the AD-specific contribution
quantitatively. Clinical trials with anti-oxidant therapy have have also shown limited efficacy. Our approach
provides quantitative readouts of AD-specific oxidative stress to optimize an anti-oxidant treatment. While
we have shown that oxidative stress results from the senile plaques of AD themselves, it is likely that other
p species, such as small diffusible aggregates, oligpmers, or Ap derived diffusible ligands (ADDLs) are also
a source of reactive oxygen species. This grant application proposes to identify aggregated and soluble Ap
components that are sources of oxidative stress, and evaluate anti-oxidant treatments for protective activity
both in vitro and in vivo using transgenic mouse models of AD. Our strength lies in the utilization of.
sophisticated imaging techniques based on multiphoton microscopy that allow us to image senile plaques
structurally and functionally in vitro and in vivo. Small diffusible aggregates of Ap like oligomers and ADDLs
can be analyzed and characterized using high-throughput plate-reader assays or multiphoton fluorescence
correlation spectroscopy (PCS). Anti-oxidants can be tested for their ability to reduce or prevent the
oxidative stress resulting from these small toxic Ap species. In combination, these experimental paradigms
will be used to screen potential anti-oxidants from both traditional and alternative sources to systematically
evaluate whether compounds like ginkgo biloba extract, vitamin E, or grape seed extract are effective anti-
oxidants for Alzheimer's disease treatment. The results will bridge the gap between the description of
oxidative stress in Alzheimer's disease to direct determination of the anti-oxidant ability of natural and
synthetic products that should hold promise for treatment of AD patients.
阿尔茨海默氏病(AD)是一种毁灭性的神经系统疾病,目前尚无治愈方法,
涉及氧化应激作为疾病的原因已经被假定了十多年。AD是
在死后的组织中以存在老年斑为特征的,老年斑是由进行性脑损伤引起的
淀粉样蛋白-p(A(3)肽的积累;因此Ap是治疗AD的主要治疗靶点。那里
有许多关于抗氧化剂治疗的研究,但没有一项研究检查AD特异性的作用,
数量上。抗氧化治疗的临床试验也显示出有限的疗效。我们的方法
提供AD特异性氧化应激的定量读数,以优化抗氧化治疗。而
我们已经表明,氧化应激是由老年性痴呆的老年斑本身引起的,很可能是其他因素引起的。
p物质,如小的可扩散聚集体、寡聚体或Ap衍生的可扩散配体(ADDL)也是可扩散的。
活性氧的来源。该拨款申请提议识别聚集的和可溶的Ap
成分是氧化应激的来源,并评估抗氧化治疗的保护活性
使用AD的转基因小鼠模型进行体外和体内研究。我们的优势在于利用。
基于多光子显微镜的先进成像技术,
在体外和体内的结构和功能。Ap样寡聚体和ADDL的小的可扩散聚集体
可以使用高通量读板仪测定或多光子荧光分析和表征
相关光谱(PCS)。抗氧化剂可以测试其减少或防止氧化的能力。
氧化应激导致这些小的有毒Ap物种。综合起来,这些实验范例
将用于筛选潜在的抗氧化剂从传统和替代来源,
评估银杏叶提取物、维生素E或葡萄籽提取物等化合物是否有效抗-
治疗阿尔茨海默病的氧化剂。这些结果将弥合描述之间的差距
阿尔茨海默病中的氧化应激,以直接测定天然和
合成产品,应持有承诺为治疗AD患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brian J Bacskai其他文献
Bringing amyloid into focus
将淀粉样蛋白置于焦点
- DOI:
10.1038/nbt0505-552 - 发表时间:
2005-05-01 - 期刊:
- 影响因子:41.700
- 作者:
Todd E Golde;Brian J Bacskai - 通讯作者:
Brian J Bacskai
Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. Gordon Research Conferences, Neurobiology of brain disorders
载脂蛋白E,尤其是载脂蛋白E4,增加淀粉样β肽的寡聚化。
- DOI:
- 发表时间:
2012 - 期刊:
- 影响因子:0
- 作者:
Tadafumi Hashimoto;Alberto Serrano-Pozo;Yukiko Hori;Hwan-Ching Tai;Kenneth W Adams;Shuko Takeda;Daniel Joyner;Diana H Thyssen;Brian J Bacskai;Matthew P Frosch;Tara L Spires-Jones;Mary Beth Finn;David M Holtzman;and Bradley T Hyman - 通讯作者:
and Bradley T Hyman
Brian J Bacskai的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brian J Bacskai', 18)}}的其他基金
Slow-wave activity as a modifier of the progression of neurodegeneration in Alzheimer's disease
慢波活动作为阿尔茨海默病神经变性进展的调节剂
- 批准号:
10657937 - 财政年份:2019
- 资助金额:
$ 25.88万 - 项目类别:
Slow-wave activity as a modifier of the progression of neurodegeneration in Alzheimer's disease
慢波活动作为阿尔茨海默病神经变性进展的调节剂
- 批准号:
10205286 - 财政年份:2019
- 资助金额:
$ 25.88万 - 项目类别:
Astrocytes as governing pathological drivers of neurovascular dysfunction in AD
星形胶质细胞是 AD 神经血管功能障碍的病理驱动因素
- 批准号:
10584240 - 财政年份:2017
- 资助金额:
$ 25.88万 - 项目类别:
CEREBRAL AMYLOID ANGIOPATHY AND MECHANISMS OF BRAIN AMYLOID ACCUMULATION
脑淀粉样蛋白血管病和脑淀粉样蛋白积累的机制
- 批准号:
9884824 - 财政年份:2016
- 资助金额:
$ 25.88万 - 项目类别:
Molecular pathways leading to neurodegeneration in vivo
导致体内神经变性的分子途径
- 批准号:
9472989 - 财政年份:2015
- 资助金额:
$ 25.88万 - 项目类别:
Molecular pathways leading to neurodegeneration in vivo
导致体内神经变性的分子途径
- 批准号:
8887495 - 财政年份:2015
- 资助金额:
$ 25.88万 - 项目类别:
A replacement multiphoton microscope for in vivo imaging in rodent models of neur
用于神经啮齿动物模型体内成像的替代多光子显微镜
- 批准号:
7595490 - 财政年份:2009
- 资助金额:
$ 25.88万 - 项目类别:
MULTIPHOTON MICROSCOPY FOR IN VIVO NEURAL IMAGING
用于体内神经成像的多光子显微镜
- 批准号:
7563694 - 财政年份:2007
- 资助金额:
$ 25.88万 - 项目类别:
Non-invasive optical imaging of neuropathology in vivo
体内神经病理学的无创光学成像
- 批准号:
7903375 - 财政年份:2006
- 资助金额:
$ 25.88万 - 项目类别:
相似海外基金
ADVANCED GLYCOSYLATION END PRODUCTS AND EFFECT OF MESANGIAL CELLS
高级糖基化最终产物和对系膜细胞的影响
- 批准号:
3776700 - 财政年份:
- 资助金额:
$ 25.88万 - 项目类别:
ADVANCED GLYCOSYLATION END PRODUCTS AND EFFECT OF MESANGIAL CELLS
高级糖基化最终产物和对系膜细胞的影响
- 批准号:
3840306 - 财政年份:
- 资助金额:
$ 25.88万 - 项目类别:
ADVANCED GLYCOSYLATION END PRODUCTS AND EFFECT OF MESANGIAL CELLS
高级糖基化最终产物和对系膜细胞的影响
- 批准号:
3855332 - 财政年份:
- 资助金额:
$ 25.88万 - 项目类别:
GLOMERULAR EFFECTS OF ADVANCED GLYCOSYLATION END PRODUCTS
高级糖基化最终产物对肾小球的影响
- 批准号:
5202002 - 财政年份:
- 资助金额:
$ 25.88万 - 项目类别:
GLOMERULAR EFFECTS OF ADVANCED GLYCOSYLATION END PRODUCTS
高级糖基化最终产物对肾小球的影响
- 批准号:
3754540 - 财政年份:
- 资助金额:
$ 25.88万 - 项目类别: